News

RAV18 is a humanized antibody targeting the ADAM9 protein on cells. ADAM9 is expressed on many solid tumors and is thought to contribute to disease progression and metastasis.

At week 48 the proportion of patients with HIV levels below detectable was over 90%. Patients who were initially treated with 3TC but who changed to apricitabine (ATC)

JR-013 is a recombinant human erythropoietin for the treatment of renal anemia in dialysis patients and Growject is currently approved and marketed in Japan to treat short stature

In addition, the FDA has reconfirmed that they would accept a positive interim or final analysis from the Impact (immunotherapy for prostate adenocarcinoma treatment) trial to amend the

The trial evaluated the efficacy, safety and tolerability of two doses of CRx-191 compared to placebo in subjects with psoriasis. In this trial, the high dose of CRx-191

Under the terms of the agreement, Bayer HealthCare will have a non-exclusive research licence for the use of BioInvent’s proprietary n-CoDeR library for the discovery of human monoclonal

White Cross will focus their marketing efforts on the over 70,000 German speaking dentists practicing in Europe. To help educate German-speaking dentists on the use of PreViser technology,

Global Medical Consulting Services (GMCS) has increased its services to offer full management to both Western and Asian pharmaceutical, biotech and medical device companies intending to conduct clinical

This investigator-sponsored Phase I clinical study was designed to assess safety, tolerability and clinical responses against metastatic melanoma after administration of plasmid-based IL-12 delivered intratumorally by Inovio’s electroporation